BjornevikKCorteseMHealyBC, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science2022; 375(6578): 296–301.
2.
LanzTVBrewerRCHoPP, et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature2022; 603(7900): 321–327.
3.
HolmøyT.The discovery of oligoclonal bands: A 50-year anniversary. Eur Neurol2009; 62(5): 311–315.
4.
LanzTVRobinsonWHHoPP, et al. Roadmap for understanding mechanisms on how Epstein-Barr virus triggers multiple sclerosis and for translating these discoveries in clinical trials. Clin Transl Immunology2023; 12(2): e1438.
5.
TengvallKHuangJHellströmC, et al. Molecular mimicry between anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk. Proc Natl Acad Sci U S A2019; 116(34): 16955–16960.
6.
ThomasOGBrongeMTengvallK, et al. Cross-reactive EBNA1 immunity targets alpha-crystallin B and is associated with multiple sclerosis. Sci Adv2023; 9: eadg3032.
7.
SattarnezhadNKockumIThomasOG, et al. Antibody reactivity against EBNA1 and GlialCAM differentiates multiple sclerosis patients from healthy controls. Proc Natl Acad Sci U S A2025; 122(11): e2424986122.
8.
LiVMcKayFCTscharkeDC, et al. Repurposing licensed drugs with activity against Epstein-Barr virus for treatment of multiple sclerosis: A systematic approach. CNS Drugs2025; 39(3): 305–320.
